Transcriptional profiles define drug refractory disease in myeloma-Reference-Cited by-同舟云学术

Transcriptional profiles define drug refractory disease in myeloma

Published:2022-05-09 Issue:3 Volume:3 Page:804-814
ISSN:2688-6146
Container-title:eJHaem
language:en
Short-container-title:eJHaem

Author:

Zhu Yuan Xiao¹,Bruins Laura A.¹,Chen Xianfeng²,Shi Chang‐Xin¹,Bonolo De Campos Cecilia¹,Meurice Nathalie¹,Wang Xuewei²,Ahmann Greg J.¹,Ramsower Colleen A.³,Braggio Esteban¹,Rimsza Lisa M.³,Stewart A. Keith⁴

Affiliation:

1. Division of Hematology‐Oncology Mayo Clinic Phoenix Arizona USA

2. Division of Biomedical Statistics and Informatics, Department of Health Science Research Mayo Clinic Rochester Minnesota USA

3. Department of Laboratory Medicine and Pathology Mayo Clinic Phoenix Arizona USA

4. Division of Medical Oncology and Hematology Princess Margaret Cancer Centre Toronto Ontario Canada

Funder

National Institutes of Health

Publisher

Wiley

Subject

General Earth and Planetary Sciences

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jha2.455

Reference49 articles.

1. Identification of a Primary Target of Thalidomide Teratogenicity

2. Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide

3. Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide

4. Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells

5. The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluation of clinical parameters and biomarkers in older, untreated mantle cell lymphoma patients receiving bendamustine–rituximab;British Journal of Haematology;2023-10-25